Bill > AB1990

This bill, concerning pharmacy law and advertising, aims to protect consumers by regulating compounded medications used for obesity or weight management. It makes it unlawful to advertise or promote these specific compounded drugs unless the advertisement is truthful and not misleading, meaning it cannot contain any unsubstantiated claims, which are statements not supported by reliable scientific evidence. Furthermore, such advertisements must include disclosures about potential side effects, adverse reactions, contraindications, precautions, and warnings, similar to those found in the labeling of FDA-approved drugs containing the same active ingredients, and must clearly state that the product is a compounded medication that has not been approved or evaluated by the FDA for safety or efficacy. The bill also introduces provisions for manufacturers and wholesalers selling bulk drug substances (also known as active pharmaceutical ingredients or APIs) for these compounded medications, requiring them to provide written verification that the substance is pharmaceutical grade and meets specific sourcing and quality control standards. Violations of these advertising and sourcing provisions can result in fines and license revocation. The bill clarifies that these new regulations do not apply to physicians and surgeons.